Compare STE & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STE | DGX |
|---|---|---|
| Founded | 1985 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 20.5B |
| IPO Year | 1992 | 1996 |
| Metric | STE | DGX |
|---|---|---|
| Price | $263.47 | $182.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $268.25 | $194.07 |
| AVG Volume (30 Days) | 674.3K | ★ 1.2M |
| Earning Date | 11-05-2025 | 10-21-2025 |
| Dividend Yield | 0.96% | ★ 1.75% |
| EPS Growth | ★ 59.39 | 14.49 |
| EPS | 6.97 | ★ 8.51 |
| Revenue | $5,702,415,000.00 | ★ $10,850,000,000.00 |
| Revenue This Year | $9.24 | $12.37 |
| Revenue Next Year | $6.30 | $3.52 |
| P/E Ratio | $37.72 | ★ $21.44 |
| Revenue Growth | 7.08 | ★ 13.74 |
| 52 Week Low | $200.98 | $148.70 |
| 52 Week High | $268.60 | $197.55 |
| Indicator | STE | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 44.87 |
| Support Level | $256.68 | $184.18 |
| Resistance Level | $268.60 | $185.12 |
| Average True Range (ATR) | 4.64 | 3.22 |
| MACD | -0.69 | -0.78 |
| Stochastic Oscillator | 65.59 | 3.85 |
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.